Home › Liver Cancer (Hepatocellular Carcinoma) › Pennsylvania
Liver Cancer (Hepatocellular Carcinoma) clinical trials in Pennsylvania
27 studies for Liver Cancer (Hepatocellular Carcinoma) are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
A Phase 1 Study of the Safety and Tolerability of CTX-10726
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07419841Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #104, Hershey
- Exelixis Clinical Site #98, Philadelphia
- Exelixis Clinical Site #32, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483National Liver Cancer Screening Trial
- University of Pennsylvania, Philadelphia
RecruitingPhase 4
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06084234A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06427941Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- Lehigh Valley Hospital, Allentown
RecruitingObservational study
Ages 22 and older · All sexes · Updated Sep 11, 2026 · NCT06486454Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06811116Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Philadelphia
- Research Site, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06921785Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Christiana Care Health System-Concord Health Center, Chadds Ford
- Geisinger Medical Center, Danville
- Geisinger Cancer Center Dickson City, Dickson City
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07166406Molecular Basis of Pediatric Liver Cancer
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
RecruitingObservational study
Ages 0 to 99 · All sexes · Updated Aug 10, 2026 · NCT03959800Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Allegheny General Hospital, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05168163A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Thomas Jefferson University, Philadelphia
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT04114136A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT06600321Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Recruiting
Ages 18 to 75 · All sexes · Updated Jun 17, 2026 · NCT05486572Y-90 Treatment Response Using Transarterial Radioembolization
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT07145801Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 20 to 99 · All sexes · Updated Apr 20, 2026 · NCT02174549Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT07223424Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT05842174Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT05733598SBRT With Atezo/Bev for HCC
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
RecruitingPhase 1
Ages 18 to 99 · All sexes · Updated Feb 20, 2026 · NCT05488522Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
- Thomas Jefferson Hospital, Philadelphia
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 26, 2026 · NCT05705219Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Penn State Hershey Medical Center, Hershey
- Albert Einstein Healthcare Network, Philadelphia
RecruitingPhase 4
Ages 18 to 64 · All sexes · Updated Jan 22, 2026 · NCT04373564Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jan 21, 2026 · NCT03539822Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2025 · NCT06698250SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Philadelphia
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.